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Abstract     59 
Dopamine signaling is a crucial part of the brain reward system and can affect feeding 60 
behavior. Dopamine receptors are also expressed in the hypothalamus, which is known 61 
to control energy metabolism in peripheral tissues. Here we show that pharmacological 62 
or chemogenetic stimulation of dopamine receptor 2 (D2R) expressing cells in the 63 
lateral hypothalamic area (LHA) and the zona incerta (ZI) decreases body weight and 64 
stimulates brown fat activity in rodents in a feeding-independent manner. LHA/ZI D2R 65 
stimulation requires an intact sympathetic nervous system and orexin system to exert its 66 
action and involves inhibition of PI3K in the LHA/ZI. We further demonstrate that, as 67 
early as 3 months after onset of treatment, patients treated with the D2R agonist 68 
cabergoline experience an increase in energy expenditure that persists for one year, 69 
leading to total body weight and fat loss through a prolactin-independent mechanism. 70 
Our results may provide a mechanistic explanation for how clinically used D2R 71 
agonists act in the CNS to regulate energy balance. 72 
 73 
 74 
 75 
 76 
  77 
 78 
  79 
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Introduction 80 
Obesity has reached epidemic prevalence, and much research has focused on 81 
homeostatic and hedonic mechanisms underlying overconsumption of food and the 82 
regulation of body weight. Dopamine has the ability to modulate food consumption by 83 
both reward (hedonic) and hypothalamic (homeostatic) pathways 1. Among the five 84 
dopamine receptors (D1R, D2R, D3R, D4R and D5R), dopamine signaling through 85 
D1R 2-4 and D2R regulates food intake 1,5-7. The increase in central dopaminergic 86 
signaling is often associated to the stimulation of feeding, while its decrease has the 87 
opposite effect; however  in the hypothalamus, the effects on food intake depend on the 88 
hypothalamic area targeted 8. 89 
 90 
The clinical relevance of the D2R is well characterized and D2R agonists such as 91 
bromocriptine and cabergoline, have been widely used for the treatment of 92 
prolactinomas. Since 2009 bromocriptine has been also approved in the United States as 93 
adjunctive treatment for type 2 diabetes 9, as it improves glucose tolerance and reduces 94 
fasting and postprandial plasma glucose levels in diabetic patients 10-12. In terms of 95 
energy homeostasis, obese humans have reduced dopamine levels and/or function 13. 96 
Antipsychotic drugs that block D2R are associated with increased appetite, weight gain 97 
and development of diabetes 14,15 and morbidly obese humans have less D2R 98 
availability 8. In addition, human studies have shown a higher prevalence of the Taq1A 99 
allele for the D2R in obese individuals 16 and genetic variants influencing D2R 100 
signaling affect a significant portion of the population 17. However, the effects of 101 
bromocriptine and cabergoline on body weight are contradictory in different studies, 102 
albeit most of them non-randomized,  reporting either reduction or no significant effects 103 
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on body weight 10,18 or no significant effects in body weight in obese or type 2 diabetic 104 
patients 19.   105 
 106 
In this study, we find that the central stimulation of D2R increases brown adipose tissue 107 
(BAT) activity in lean and diet-induced obese rodents in a food intake-independent 108 
manner. These central effects are located in GABAergic neurons in the lateral 109 
hypothalamic area (LHA) and the neighboring zona incerta (ZI). D2R triggers orexin 110 
signaling, which leads to decreased protein kinase A (PKA) activity, increased 111 
phosphodiesterase 3B (PDE3B) and reduced ribosomal protein S6 (rpS6) levels. Of 112 
note, this thermogenic action depends on the sympathetic nervous system (SNS). 113 
Importantly, the clinical relevance of these findings is supported by the fact that patients 114 
treated with cabergoline for 12 months showed a significant weight loss, associated with 115 
augmented resting energy expenditure, alongside metabolic improvement, through a 116 
prolactin-independent mechanism. 117 
  118 
Results 119 
Bromocriptine induces negative energy balance and thermogenesis 120 
A single ICV injection of bromocriptine (40 and 80 µg/rat) significantly decreased body 121 
weight after 24 hours independently of food or water intake, while a dose of 20 µg/rat 122 
did not change body weight (Supplementary Fig. 1a-d). The dose of 80 µg/rat elicited a 123 
significant early increase in food intake but after 24 hours the food intake was similar 124 
between control and bromocriptine-treated animals. ICV bromocriptine-treated rats (40 125 
µg/rat) showed increased energy expenditure (Supplementary Fig. 1e), BAT 126 
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interscapular temperature (Supplementary Fig. 1f) and stimulation of 2-18F-fluoro-2-127 
deoxy-2-glucose (18F-FDG) uptake in BAT analyzed by positron emission 128 
tomography-computed tomography (PET-CT) (Supplementary Fig. 1g); while no 129 
changes were found in body temperature or respiratory quotient (Supplementary Fig. 130 
1h-i). Consistently, the analysis of histological sections revealed smaller lipid droplets 131 
in adipocytes of BAT from bromocriptine-treated rats (Supplementary Fig. 1j), 132 
increased BAT UCP1 protein levels (Supplementary Fig. 1k) and increased tolerance to 133 
cold exposure (Supplementary Fig. 1l). As expected, the central activation of D2R 134 
stimulated locomotor activity at short-term (Supplementary Fig. 1m). To determine the 135 
relevance of physical activity on energy expenditure in relation to non-physical activity 136 
mechanisms (e.g. resting metabolic rate), we performed correlations and found that 137 
energy expenditure and locomotor activity were positively correlated in the dark phase 138 
(right panel) but not in the light phase (left panel) (Supplementary Fig. 1n). In addition, 139 
we have also analyzed energy expenditure (Kcal/h) during 2 hours of the light phase 140 
when animals were less active. During these 2 hours of the light phase, we did not see 141 
any difference in energy expenditure between vehicle and bromocriptine treated rats 142 
(Supplementary Fig. 1o), suggesting that bromocriptine is not affecting resting 143 
metabolic rate. Bromocriptine and cabergoline are used in patients with prolactin144 
secreting pituitary adenomas 20, but circulating levels of prolactin in rats treated with 145 
bromocriptine ICV remained unchanged when compared to control groups 146 
(Supplementary Fig. 1p).  147 
 148 
In addition, we injected prolactin ICV in male mice at two different doses (1 and 10 149 
µg/mouse) and after 24 hours (when bromocriptine caused a significant reduction in 150 
body weight independent of food intake), we failed to find any statistically significant 151 
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effect on body weight and food intake (Supplementary Fig. 2a,b). In keeping, prolactin 152 
ICV did not affect BAT interscapular temperature (Supplementary Fig. 2c). Overall, 153 
these results indicate that the central administration of prolactin is not altering BAT 154 
activity.   155 
 156 
To rule out the possibility that centrally injected bromocriptine leaks out of the CNS 157 
into the circulation and elicits a response by directly acting at peripheral level, we 158 
administered bromocriptine peripherally, using the same dose as the one injected 159 
centrally. We were unable to detect changes in food intake, body weight or BAT 160 
temperature (Supplementary Fig. 3a-c). Consistent with this, when we injected an 161 
adenoviral vector encoding a shRNA against D2R in the BAT 21, the knockdown of 162 
D2R specifically in BAT (Supplementary Fig. 3d,e) did not prevent the effects of 163 
central bromocriptine on body weight (Supplementary Fig. 3f), food intake 164 
(Supplementary Fig. 3g), BAT interscapular temperature (Supplementary Fig. 3h) or 165 
BAT UCP-1 levels (Supplementary Fig. 3i). In addition, to assess whether the effect of 166 
bromocriptine on BAT was sex-dependent or not, we injected a single ICV injection of 167 
bromocriptine (40 µg/rat) in females, and found that identically to males, it significantly 168 
decreased body weight and white fat mass after 24 hours, concomitant with increased 169 
BAT interscapular temperature, and this effect was again independent of food intake 170 
(Supplementary Fig. 4a-e). 171 
 172 
We next investigated if the effects of central bromocriptine may be long-lasting. 173 
Therefore, we chronically infused bromocriptine (40 µg/rat) during 2 weeks in rats fed a 174 
chow diet. We found that cumulative food intake remained unchanged, while body 175 
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weight gain was significantly lower in rats treated with bromocriptine (Fig. 1a,b). 176 
Histological analyses revealed smaller lipid droplets in BAT of bromocriptine-treated 177 
rats, as well as increased protein content of UCP1, FGF21 and PRDM16 (Fig. 1c,d). β-178 
adrenergic receptors represent a key link involved in the regulation of adipose tissue 179 
metabolism by the sympathetic nervous system (SNS) 22,23. To determine whether the 180 
central bromocriptine action on BAT was mediated by SNS, we injected the β3 181 
adrenergic receptor specific antagonist SR59230A 24,25 and found that it reversed the 182 
effects of central bromocriptine on weight gain (Fig. 1a), BAT lipid content and BAT 183 
levels of thermogenic markers (Fig. 1c,d). After that, we assessed the efficacy of the 184 
chronic central infusion of bromocriptine in diet-induced obese (DIO) rats. Similarly, to 185 
the results obtained in rats fed a chow diet, central bromocriptine reduced body weight 186 
gain and adiposity in a feeding independent manner (Fig. 1e-g). Consistently, energy 187 
expenditure was also higher (Fig. 1h), with changes neither in respiratory quotient nor 188 
locomotor activity (Fig. 1i,j). BAT from bromocriptine-treated DIO rats showed smaller 189 
lipid droplets and increased protein content of thermogenic markers (Fig. 1k,l). 190 
Moreover, the pharmacological blockade of the β3 adrenergic receptor reversed the 191 
effects of central bromocriptine on weight gain, adiposity, energy expenditure, as well 192 
as BAT morphology and protein levels of UCP1 (Fig. 1f-l). To finally characterize the 193 
relevance of the SNS, triple knockout (TKO) (β1-, β2-, and β3-adrenergic receptors) 194 
mice were centrally infused with bromocriptine for 7 days. Bromocriptine did not affect 195 
food intake in WT or TKO mice, but significantly decreased body weight gain and 196 
white fat mass in WT mice, but not in TKO mice (Fig. 1m-o). In agreement with this, 197 
central bromocriptine reduced BAT lipid content and increased BAT UCP1 protein 198 
levels in WT but not in TKO mice (Fig. 1p,q).   199 
 200 
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D2R in the LHA and ZI activates BAT in diet-induced obese (DIO) rats 201 
D2R is widely expressed in the hypothalamus 26. Therefore, we examined the specific 202 
activation of the dopaminergic system in different hypothalamic sites. We found that a 203 
single injection of bromocriptine in the LHA and the zona incerta (ZI) (Supplementary 204 
Fig. 4f) of rats fed a chow diet decreased body weight and stimulated BAT temperature 205 
after 24 hours in a feeding-independent manner (Supplementary Fig. 4g-i). In these 206 
animals, circulating levels of prolactin did not change significantly compared to control 207 
groups (Supplementary Fig. 4j). When vehicle or bromocriptine were injected in the 208 
VMH of rats fed a chow diet (Supplementary Fig. 4k), we found that body weight of 209 
vehicle-treated rats decreased after 24 hours, but bromocriptine-treated animals lost 210 
more weight and shower higher BAT temperature than controls independent of changes 211 
in feeding (Supplementary Fig. 4l-n). Notably, the central injection of bromocriptine in 212 
the LHA/ZI (Fig. 2a-e), but not within the VMH (Fig. 2f-h), of DIO rats reduced body 213 
weight, increased interscapular temperature, reduced the lipid content in BAT and 214 
increased BAT UCP1 protein levels without changing food intake (Fig. 2a-h).  215 
We next used a designer receptor exclusively activated by designer drugs (DREADD) 216 
approach to specifically activate D2R neurons in the LHA and the ZI. D2R-Cre mice 217 
fed a chow diet were bilaterally injected with AAV-hSyn-DIO-hM3D(Gq)-mCherry in 218 
the LHA and the ZI, where its expression was located (Fig. 2i). More specifically, D2R-219 
mCherry neurons occupy the LHA area defined by the fornix/perifornical nucleus, the 220 
nigrostriatal bundle, cerebellar peduncle, and the medial tuberal nucleus. After 3 weeks, 221 
activation of hM3D(Gq)-mCherry by intraperitoneal (i.p.) injections of clozapine-N-222 
oxide (CNO) (1mg/kg) leads to a decrease in body weight without changes in feeding 223 
and water intake (Fig. 2j,k). The decrease in body weight was associated with higher 224 
interscapular temperature, energy expenditure and BAT UCP1 protein levels, alongside 225 
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decreased lipid content in BAT with unaltered body temperature, respiratory quotient, 226 
locomotor activity, resting metabolic rate or plasma prolactin levels (Fig. 2l-t). When 227 
animals were exposed to 4ºC, the group where D2R were activated in the LHA/ZI 228 
showed a cold resistance as demonstrated by an increased capacity to maintain body and 229 
BAT temperature (Fig. 2u). 230 
Since clozapine metabolite rather than CNO has been shown to mediate the activation 231 
of DREADD receptor after i.p injection 27 and clozapine has some affinity with D2R, 232 
we also performed an independent experiment using this compound. Similar to CNO, 233 
the injection of clozapine decreased body weight and stimulated BAT temperature 234 
(Supplementary Fig. 4o,q). We next evaluated the phenotype of mice after 235 
chemogenetic activation of D2R neurons at thermoneutrality (30 ºC). At 30 ºC, the 236 
activation of D2R neurons in the LHA and ZI resembled the effects found at 23 ºC 237 
described above, as the mice presented lower body weight, increased interscapular 238 
temperature and energy expenditure without changes in body temperature or locomotor 239 
activity (Supplementary Fig. 5a-f). We also performed correlations between energy 240 
expenditure and locomotor activity but failed to find any correlation (Supplementary 241 
Fig. 5g). In addition, energy expenditure did not change during the 2 hours of the light 242 
phase when animals were less active, suggesting that activation of D2R neurons in the 243 
LHA/ZI is not affecting resting metabolic rate (Supplementary Fig. 5g). 244 
 245 
To test whether D2R neurons located in other hypothalamic areas were also important 246 
for the regulation of BAT activity, we performed chemogenetic activation of D2R 247 
neurons in the mediobasal hypothalamus (MBH: ARC + VMH) including the 248 
tuberoinfundibular dopamine (TIDA) neurons controlling prolactin secretion from the 249 
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anterior pituitary 28, and in the dorsomedial nucleus of hypothalamus (DMH). We found 250 
that chemogenetic activation of D2R neurons in the MBH and DMH did not affect body 251 
weight, interscapular temperature or white fat mass (Supplementary Fig. 6).  252 
 253 
The effect of bromocriptine on BAT is dependent on D2R in the LHA/ZI 254 
We stereotaxically delivered an adenoviral vector encoding a shRNA against D2R in the 255 
LHA/ZI in rats fed a chow diet. Infection efficiency in the LHA and ZI was assessed by 256 
expression of GFP and decreased levels of D2R (Fig. 3a,b). Although the selected titer 257 
of the adenoviral vector inhibiting D2R in the LHA/ZI did not affect either body weight 258 
or food intake, it attenuated bromocriptine–induced weight loss (Fig. 3c,d). In 259 
agreement with these results, the effect of bromocriptine on adiposity, BAT 260 
temperature, lipid content and UCP1 levels was absent when D2R was inhibited in the 261 
LHA/ZI (Fig. 3e-h). Furthermore, rats receiving bromocriptine in the LHA/ZI displayed 262 
a significant increase in c-FOS staining in the raphe pallidus (RPa) and the inferior olive 263 
(IO), which was indicative of higher neuronal activation (Fig. 3i).  264 
 265 
However, the knockdown of D2R in the VMH (Supplementary Fig. 7a) of rats fed a 266 
chow diet did not ameliorate bromocriptine–induced weight loss, adiposity or 267 
interscapular temperature (Supplementary Fig. 7b-e). To further confirm the relevance 268 
of the LHA/ZI in the actions of bromocriptine, we performed another experiment 269 
injecting in the LHA/ZI the adenoviral vector inhibiting D2R (Supplementary figure 7f) 270 
and two weeks later, mice were treated with systemic bromocriptine at a dose higher 271 
than the one administered ICV. This intraperitoneal dose (5 mg/kg) decreased body 272 
weight, WAT mass and activated BAT temperature and UCP1 protein levels 273 
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(Supplementary Fig. 7g-k). However, these effects were completely abolished when the 274 
D2R was inhibited in the LHA/ZI (Supplementary Fig. 7g-k).    275 
 276 
D2R action in GABAergic neurons requires orexin to modulate BAT  277 
The LHA and the ZI are mainly composed by multiple neuronal populations expressing 278 
different neuropeptides and neurotransmitters. To identify which neuronal populations 279 
were expressing D2R, we used a D2R-cre:ribotag mouse line 29. HA immunoreactivity 280 
allowing the identification of D2R-positive cells was detected in GABAergic and 281 
glutamatergic neurons in the LHA and the ZI, but not in cells expressing MCH or 282 
orexin (Fig. 3j). To know the functional relevance of GABAergic and glutamatergic 283 
neurons in the actions of D2R, we over-expressed D2R in these neuronal populations 284 
injecting a viral vector (Ad-hSyn-DIO-D2R) in the LHA/ZI of Vglut2- ires-cre and 285 
Vgat-ires-cre mice. Fluorescent activated cell sorting (FACS) demonstrated that the 286 
virus targeted 198.2 ± 10.2 cells per animal in the LHA/ZI and confirmed D2R 287 
expression in GABAergic and glutamatergic neurons (Fig. 4g). The gating strategy for 288 
FACS is detailed in Supplementary fig 8. We found that over-expression of D2R in 289 
GABAergic (Fig. 4f-k), but not glutamatergic cells of the LHA/ZI (Fig. 4a-e), reduced 290 
body weight and increased interscapular temperature and UCP1 protein levels 291 
independent of food intake. In line with this, the inhibition of D2R in GABAergic 292 
neurons of the LHA/ZI using a viral vector expressing a shRNA against D2R (Ad-hSyn-293 
DIO-shD2R) increased body weight and decreased interscapular temperature when 294 
compared to control mice (Fig. 4l-o).   295 
Since GABA regulates the activity of different neuronal populations in the LHA, we 296 
next tested whether the effects of the hypothalamic dopamine system required orexin or 297 
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MCH, two neuropeptides known to be involved in thermoregulation 30,31. We found that 298 
bromocriptine administered ICV increased orexin, but not MCH, mRNA levels in the 299 
LHA (Supplementary Fig. 9a). Similarly, bromocriptine directly injected in the LHA/ZI 300 
augmented orexin protein levels (Supplementary Fig. 9b), the knockdown of D2R in the 301 
LHA/ZI prevented bromocriptine-induced orexin protein levels (Supplementary Fig. 302 
9c), and the chemogenetic activation of D2R in LHA/ZI stimulated orexin levels 303 
(Supplementary Fig. 9d). The specific isolation of the LHA/ZI was corroborated by 304 
measuring protein levels of orexin and MCH, which are specifically located in the LHA 305 
and were not detected in the VMH (Supplementary Fig. 9e). Although there are no 306 
specific markers for the ZI, the isolated micropunches included the LHA and also ZI, 307 
because due to their neighboring localization and the lack of specific markers, it is 308 
virtually impossible to separate it from the LHA. Moreover, the specificity of the 309 
antibodies for D2R, orexin and MCH was tested in D2R null mice, orexin null mice and 310 
rats injected with an MCH antisense oligonucleotide respectively (Supplementary Fig. 311 
10a).    312 
To investigate the mechanistic link between LHA D2R and the orexin system, we next 313 
assessed the effects of central bromocriptine in mice lacking orexin. We found that 314 
while in WT mice bromocriptine decreased body weight in a food-independent manner, 315 
increased interscapular temperature, decreased lipid content in BAT and up-regulated 316 
BAT UCP-1 protein levels, it was unable to exert these actions in orexin-deficient mice 317 
(Fig. 4p-t).  318 
To further characterize the role of orexin as a mediator of dopamine actions, we 319 
performed chemogenetic stimulation of D2R neurons in the LHA/ZI and concomitant 320 
treatment with the orexin receptor 1 antagonist SB-334867 32. Our findings 321 
demonstrated that the effects of D2R activation in the LHA/ZI on body weight, 322 
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interscapular temperature, BAT lipid content and UCP1 levels were completely blocked 323 
when SB-334867 was injected ICV (Fig. 4u-x). 324 
 325 
Phosphodiesterase 3B and protein kinase A mediate the actions of bromocriptine   326 
Protein kinase A (PKA) signaling has been related to non-metabolic dopamine D2R 327 
actions in some extra-hypothalamic areas 33,34. Herein, we measured phosphorylated 328 
cAMP response element-binding protein (pCREB) as a marker of PKA activity 35. We 329 
found that both bromocriptine administered either ICV or in the LHA/ZI (Fig. 5a,b) and 330 
chemogenetic activation of D2R in the LHA/ZI (Fig. 5c) decreased pCREB protein 331 
levels, an effect that was blunted by the injection of the orexin receptor 1 antagonist 332 
(Fig. 5c). This decrease in pCREB levels was also detected after the injection of orexin 333 
A, an effect blocked by the orexin receptor 1 antagonist (Fig. 5d). Thus, these data 334 
indicate that both bromocriptine and orexin modulate PKA activity. 335 
 336 
Central injection of the specific PKA activator Sp-cAMPS (90 ng/rat) 35,36, abolished 337 
the effects of bromocriptine on body weight, white mass, BAT interscapular 338 
temperature, lipid content and UCP1 protein levels in a feeding-independent manner 339 
after 24h (Fig. 5e-j). Furthermore, the administration of the PKA inhibitor H-89 (62 340 
ng/rat) 35,36 in the LHA/ZI recapitulated the effects of bromocriptine, since it decreased 341 
body weight, white mass and BAT lipid content and stimulated BAT interscapular 342 
temperature and UCP1 protein levels (Fig. 5k-p) independent of food intake. 343 
 344 
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Phosphodiesterases (PDEs) are enzymes that break a phosphodiester bond and are 345 
classified in different families. PDE3 is highly sensitive to inhibition of cAMP 346 
hydrolysis by cGMP, and there are 2 PDE3 isoforms which are encoded by different 347 
genes (PDE3A and PDE3B) 37. Hypothalamic PDE3B was found to play a relevant role 348 
regulating the action of leptin on feeding 38 and insulin 39. PDE3B is also related to 349 
hypothalamic leptin signaling during the development of diet-induced obesity 40. We 350 
measured protein levels of PDE3B in the LHA/ZI of mice and found that after the 351 
chemogenetic stimulation of D2R in this hypothalamic area, PDE3B levels were 352 
increased compared to control mice (Fig. 5q). Then, we injected ICV the PDE3 353 
inhibitor cilostamide at a reported dose (10 µg/mouse) 39 that did not affect body weight 354 
or food intake (Fig. 5r,s). However, this dose of cilostamide blocked the effects of 355 
chemogenetic activation of D2R on body weight and interscapular temperature (Fig. 5t-356 
v). Finally, we injected cilostamide ICV in mice where D2R was over-expressed in 357 
GABA neurons injecting the Ad-hSyn-DIO-D2R in the LHA/ZI of Vgat-ires-cre mice; 358 
our data showed that cilostamide ameliorated the suppression of body weight and 359 
stimulation of BAT activity and increased energy expenditure induced by D2R 360 
overexpression in GABA neurons (Fig. 5w-z). Overall, these results indicate that 361 
PDE3B mediates the central effects of the hypothalamic dopamine system within 362 
LHA/ZI on body weight and BAT activity. 363 
 364 
rpS6 in the LHA/ZI modulates the actions of bromocriptine  365 
PKA has been identified to regulate ribosomal protein S6 (rpS6) 41,42. Thereby, we 366 
investigated the possibility that rpS6 was mediating the actions of bromocriptine on 367 
energy balance. Phosphorylated levels of rpS6 (P-rpS6) were significantly decreased 368 
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after the injection of bromocriptine ICV (Fig. 6a,b) or in the LHA/ZI (Fig. 6c), an effect 369 
that was blunted when D2R was knocked down specifically in the LHA/ZI (Fig. 6d) and 370 
when bromocriptine was injected in orexin-deficient mice (Fig. 6e). The chemogenetic 371 
activation of D2R in the LHA/ZI also resulted in lower P-rpS6 protein levels, and this 372 
effect was prevented by the antagonism of orexin receptor 1 (Fig. 6f). In line with this, 373 
orexin, which also down-regulates P-rpS6 levels failed to do that when the orexin 374 
receptor 1 antagonist was given (Fig. 6g). These results suggest that both D2R and 375 
orexin signaling were important for the modulation of P-rpS6. Importantly, the effects 376 
of bromocriptine on P-rpS6 were specific, because when we measured hypothalamic 377 
protein levels of multiple molecules known to have important effects on energy 378 
homeostasis such as phosphorylated c-Jun N-terminal kinase (pJNK), JNK, 379 
phosphorylated protein kinase B (pAKT), AKT or mammalian target of rapamycin 380 
(mTOR), they remained unaltered after bromocriptine treatment (Supplementary Fig. 381 
10b). In addition, we found that the administration of H-89 in the LHA/ZI decreased P-382 
rpS6 levels (Fig. 6h), and that the activation of PKA by Sp-cAMPS blunted 383 
bromocriptine-induced rpS6 inhibition (Fig. 6i). 384 
 385 
Given that rpS6 was regulated by bromocriptine/orexin/PKA, we next performed a 386 
functional study using an adenovirus encoding a constitutive active form of S6K (CA-387 
S6K-Ad) 43 in the LHA/ZI. We confirmed the efficiency of the viral vector by detecting 388 
increased P-rpS6 protein levels 8 days after the stereotaxic administration of CA-S6K-389 
Ad (Fig. 6j). Although the dose of the adenoviral vector activating S6K in the LHA/ZI 390 
did not affect food intake or body weight, it attenuated bromocriptine–induced weight 391 
loss (Fig. 6k,l), the increase in interscapular temperature (Fig. 6m), the reduction of 392 
lipid content in BAT (Fig. 6n) and the up-regulation of BAT UCP1 (Fig. 6o). To note, 393 
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the activation of S6K did not modify the bromocriptine-induced orexin levels in the 394 
LHA/ZI, confirming that rpS6 is downstream orexin (Ad Null LHA/ZI+ Vehicle ICV: 395 
100± 9.1, Ad Null LHA/ZI + BC (40ug/rat)ICV: 136.7±9.6, Ad S6K1 LHA/ZI+ 396 
Vehicle ICV:104,0± 8.9, Ad S6K1 LHA/ZI+ BC (40ug/rat) ICV: 126,2±6.8). 397 
 398 
Dopamine agonism decreases body weight in hyperprolactinemic patients  399 
In the retrospective study after one year of cabergoline treatment instauration with 0.5 400 
mg twice weekly all patients normalized the hyperprolactinemia irrespective of sex. 401 
Side effects were infrequent and very mild (nausea and postural hypotension) and no 402 
patient was withdrawn from the treatment for this reason. A statistically significant 403 
decrease in body weight and BMI were observed (Table 1 and Fig. 7a). Noteworthy, a 404 
huge inter-individual variability in weight loss was evident (Fig. 7a). Of interest, after 405 
12 months of cabergoline treatment a statistical improvement in glucose metabolism as 406 
evidenced by decreases in glucose and insulin concentrations as well as in the insulin 407 
resistance HOMA-IR index was observed. The same was true for the lipid profile with 408 
significant reductions in the levels of triglycerides, total and LDL cholesterol. No sex 409 
differences were observed as regards both the anthropometric and metabolic changes. 410 
 411 
Dopamine agonism increases energy expenditure in hyperprolactinemic patients  412 
To gain more insight into the potential impact of dopamine agonism on body weight, 413 
body composition, resting energy expenditure and metabolic changes were analysed in a 414 
prospective study in patients affected by hyperprolactinemia. As observed in the 415 
retrospective study one year after cabergoline treatment instauration with 0.5 mg twice 416 
weekly all patients normalized the hyperprolactinemia irrespective of sex. Side effects 417 
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were again infrequent and very mild (nausea, postural hypotension and dizziness) with 418 
no patient withdrawing from the treatment. In this case, the statistically significant 419 
reduction in body weight and BMI was already observed after 3 months of cabergoline 420 
treatment start (Fig. 7b) and persisted after 12 months (Table 1). Again, patients 421 
exhibited a huge inter-individual variability in weight loss both after 3 and 12 months 422 
following cabergoline treatment irrespective of the weight category (Fig. 7b). The 423 
magnitude of weight loss was greater after 3 as compared to 12 months. Noteworthy, 424 
following cabergoline treatment body composition analysis showed a significant 425 
decrease of both total and visceral adiposity as evidenced by reduction of body fat 426 
percentage and waist circumference, respectively (Table 1). In line with the 427 
anthropometric changes observed, a statistically significant increase in REE was 428 
documented expressed in absolute terms or adjusted by either total body weight or fat-429 
free mass. Importantly, patients showed the REE predicted from the Harris Benedict 430 
equation before starting the cabergoline treatment, however after 3 months of treatment 431 
the REE was significantly higher than the theoretical REE (Fig. 7c); and there was a 432 
positive correlation between the REE adjusted per body weight after cabergoline 433 
treatment and weight loss (Fig. 7d). Cabergoline treatment was followed by a 434 
significant improvement in glucose metabolism as evidenced by decreases in glucose 435 
and insulin concentrations as well as in the insulin resistance HOMA-IR index which 436 
was already evident after 3 months. Triglyceride concentrations experimented also a 437 
significant decrease after 3 and 12 months of cabergoline start, although in this case no 438 
changes in total, LDL and HDL cholesterol levels were observed. As in the 439 
retrospective study, no significant differences in the anthropometric, REE and metabolic 440 
effects between men and women took place.  441 
 442 
19 
 
Discussion 443 
Our findings indicate that the brain dopamine system directly activates BAT 444 
thermogenesis in a feeding-independent manner. More specifically, these actions are 445 
mediated by the stimulation of D2R in GABAergic neurons located within the LHA and 446 
the ZI, which activates the SNS and ultimately leads to the increase of UCP1, BAT 447 
temperature and energy expenditure. This process is mediated by the up-regulation of 448 
orexin and PDE3B, which in turn decreases cAMP and the activity of PKA and rpS6. 449 
To our knowledge, these findings are the first to provide information about the brain site 450 
and mechanisms by which fat mass decreases in response to a stimulation of CNS D2R 451 
activity, independently of anorexigenic actions. We also observed that patients treated 452 
with cabergoline, a D2R agonist, for 12 months showed a reduction in BMI and body 453 
fat together with an increase in resting energy expenditure and an improvement in 454 
glucose and lipid metabolism. 455 
The mechanisms by which central dopamine affects body weight are widely assumed to 456 
be related to food intake and reward 17,44. Within the hypothalamus, dopamine levels in 457 
the LHA immediately increase in response to feeding and normalize after meal 458 
consumption 45-47, and injection of D2R antagonists in the LHA reverses amphetamine-459 
induced anorexia 48,49. However, dopamine levels in the VMH decrease after feeding 460 
and increase during fasting 50 and dopamine injection in this area increased meal size 461 
while decreasing meal number 51. In line with this, tyrosine hydroxylase neurons of the 462 
ARC excited AgRP neurons and inhibited POMC neurons, suggesting that dopamine 463 
has an orexigenic action in this hypothalamic site 52. More recently, one report has 464 
shown that activation of striatal D2R reduced BAT thermogenesis and energy 465 
expenditure, and accelerated obesity despite reduced eating 53. That study supports the 466 
idea that the dopamine system may exert different actions depending on the 467 
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hypothalamic site. Nevertheless, some report showed that although chronic obesogenic 468 
diets reduce striatal D2R function, striatal D2R down-regulation does not lead to obesity 469 
54,55, suggesting that changes in striatal D2R expression could be a consequence rather 470 
than the cause of obesity.  471 
 472 
In addition to the well-known effects on food intake, the hypothalamic areas where D2R 473 
is highly expressed, are also important centers for the control of BAT activity 56. 474 
Therefore, we hypothesized that D2R stimulation at this level could trigger BAT 475 
thermogenesis. We found that chronic central infusion of bromocriptine increases BAT 476 
activity and ameliorates diet-induced obesity, independently of feeding. These effects 477 
are regulated by the SNS, since its pharmacological or genetic disruption blunts 478 
bromocriptine-induced effects on BAT. The hypothalamic area responsible for the 479 
effects of bromocriptine resides in the LHA and the ZI, since pharmacological and 480 
chemogenetic stimulation of D2R in these areas reduces HFD-induced adiposity due to 481 
increased BAT activity and higher energy expenditure. The chemogenetic stimulation of 482 
D2R neurons in the LHA/ZI, but not in the VMH or DMH, also stimulated BAT activity 483 
and decreased adiposity in conditions of thermoneutrality. Supporting these data, the 484 
loss-of-function of D2R by shRNA in the LHA/ZI was enough to block the actions of 485 
central and peripheral bromocriptine on BAT function. Therefore, these results indicate 486 
that the site of action of the dopamine system to regulate BAT activity occurs 487 
specifically in the LHA/ZI but not in other hypothalamic regions.   488 
 489 
In line with this, even though dopamine receptors have been detected in brown 490 
adipocytes and dopamine stimulates thermogenesis in these cells 57, when we inhibited 491 
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D2R in BAT, central bromocriptine was still able to decrease body weight and increase 492 
BAT temperature. Overall, our in vivo results indicate that the thermogenic action of 493 
bromocriptine requires the presence of D2R in the LHA/ZI, while D2Rs located in BAT 494 
are not necessary. Previous reports have suggested that the effects on food intake occur 495 
in the ARC and VMH and our present findings indicate that chemogenetic activation of 496 
D2R in the MBH, which includes ARC and VMH, or in the DMH, does not affect BAT 497 
thermogenesis while D2R neurons in the LHA and ZI regulate BAT and increase energy 498 
expenditure. Therefore, the effects of dopamine on food intake from those on energy 499 
expenditure are dissociated since dopamine requires the ARC to regulate food intake 52 500 
and the present study indicates that dopamine actions in the LHA and ZI controls BAT 501 
activity and energy expenditure.  502 
 503 
The LHA and ZI are heterogeneous brain areas containing numerous genetically distinct 504 
cell populations that use a plethora of signaling mechanisms. Our findings indicate that 505 
D2R is located in both glutamatergic and GABAergic cells, but only genetic 506 
manipulation of D2R only in GABAergic neurons exert marked effects on body weight. 507 
This is of relevance because both GABA neurons and dopamine modulate orexin 508 
activity 58,59. A key role of orexin is related to energy expenditure via the regulation of 509 
thermogenesis  31,32,60,61. However, despite these data it was totally unknown whether 510 
the interaction with central dopamine system could play a significant role in energy 511 
homeostasis. To address that possibility, we investigated whether the central 512 
thermogenic effect of bromocriptine was associated with orexin function. Our findings 513 
indicate that central stimulation of D2R increased orexin expression and that 514 
bromocriptine failed to activate BAT thermogenesis in orexin-deficient mice. In 515 
agreement with this, the effect of the chemogenetic stimulation of D2R neurons in the 516 
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LHA/ZI was blunted after the central blockade of the OX1R. Thus, our results indicate 517 
that orexin mediates the thermogenic effects of brain D2R stimulation.  518 
 519 
Dopamine has been related with cAMP-dependent signaling. More precisely, the 520 
activation of D2R inhibits 62, while the D2R antagonist haloperidol promotes the 521 
stimulation of cAMP-dependent PKA and increased the phosphorylation of rpS6 in 522 
neurons of the striatum 42. Moreover, phosphodiesterase (PDE), and more precisely 523 
PDE3B is highly sensitive to inhibition of cAMP hydrolysis by cGMP 37. Hypothalamic 524 
PDE3B, plays a relevant role regulating the action of leptin 38 and insulin 39. Our results 525 
indicate that PDE3B mediates the central effects of the dopamine system on body 526 
weight and BAT activity. Thus, our current model is that high levels of PDE3B degrade 527 
cAMP and these low levels of cAMP subsequently determine the low activity of PKA. 528 
Hypothalamic PKA 35,63 and rpS6 43 have been reported to play a relevant role in the 529 
control of energy balance, but their role within the LHA is still unexplored. 530 
Furthermore, PKA has been identified as a regulator of rpS6 in neuronal cells 42. 531 
Therefore, we hypothesized that bromocriptine might be using this pathway in the LHA 532 
to exert its actions on BAT. Our findings demonstrate that both pharmacological and 533 
chemogenetic activation of D2R decreased PKA activity, measured by the surrogate 534 
marker pCREB. Accordingly, the direct injection of the PKA inhibitor named H-89 in 535 
the LHA/ZI stimulated BAT activity and decreased body weight, and the activation of 536 
PKA by Sp-cAMPS totally blunted bromocriptine effects on weight loss, BAT 537 
temperature and UCP1 expression. Overall, these results indicate that bromocriptine-538 
mediated actions on BAT activity are mediated by PKA-catalyzed phosphorylation of 539 
rpS6. In line with our findings, previous studies showed that the inactivation of central 540 
PKA, achieved by the disruption of several of its subunits causes resistance to diet-541 
23 
 
induced obesity 64,65. However, to our knowledge, this is the first study addressing the 542 
relevant role of PKA in the LHA/ZI.  543 
 544 
In line with the findings made in rodents, dopamine agonism in both our retrospective 545 
and prospective studies of hyperprolactinemic patients decreased body weight and 546 
improved glucose and lipid metabolism. The weight loss was accompanied by a 547 
reduction in both total body fat and visceral adiposity. Interestingly, dopamine agonism 548 
achieved by cabergoline treatment in hyperprolactinemic patients resulted in an increase 549 
in REE which is consistent with the bromocriptine-induced effects on BAT observed in 550 
rodents. Moreover, in patients treated with cabergoline, the weight loss is positively 551 
correlated to REE. Our observations are in agreement with previous studies of 552 
bromocriptine or cabergoline treated patients 66-68. Noteworthy, while cabergoline 553 
decreases body weight in both lean and overweighed patients irrespective of BMI a 554 
clear variability in this response is observed, and patients with higher BMIs are in a 555 
position of losing more excess weight. Our preclinical studies indicate that prolactin is 556 
not mediating the effects of bromocriptine nor chemogenetic manipulation of 557 
neuroendocrine TIDA neurons on body weight and BAT activity. In line with this, in 558 
human studies it is unlikely that weight loss is secondary to normalization of prolactin, 559 
because all the patients with prolactinomas treated with cabergoline showed a 560 
normalization in prolactin levels. Despite that prolactin levels are normalized in all 561 
these patients treated with cabergoline, they showed changes in body weight. Therefore, 562 
there is no correlation between circulating prolactin levels and body weight.  563 
 564 
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In summary, this study reveals that the activation of D2R in GABA neurons within the 565 
LHA and ZI stimulates orexin and PDE3B, which lowers cAMP levels and inhibits a 566 
PKA-rpS6. This increases SNS tone, upregulates BAT thermogenesis, and increases 567 
energy expenditure, leading to weight loss. In line with this, patients undergoing 568 
treatment with the dopamine agonist cabergoline experimented an increase in energy 569 
expenditure, leading to total body weight and fat loss. Therefore, this study provides 570 
mechanistic insight into the mechanisms taking place at the CNS by which 571 
bromocriptine/cabergoline exert their beneficial effects on energy balance and 572 
metabolic homeostasis in the clinical setting. 573 
 574 
Material and Methods 575 
 576 
Animals and diets 577 
Male and female Sprague-Dawley rats (200-250 g); WT and triple b-adrenoreceptor 578 
(AR) knockout (TKO) male mice (weight 20–25 g, age 8–10 weeks old) 69,70; WT and 579 
orexin knockout male mice (null Ox/Hcrt mice, orexin/hypocretin; B6.129S6-580 
Hcrttm1Ywa/J, The Jackson Laboratory) (weight 25–30 g, age 10–12 weeks old)  32, 581 
WT and Drd2-cre male mice (C57BL/6J, weight 20–25 g, age 8–10 weeks old) 71, 582 
Drd2-cre:riboatg mice (weight 25-30 g, age 8-10 weeks old) 29, vgat-ires-cre knock-in 583 
(C57BL/6J) and vglut2-ires-cre knock-in (C57BL/6J) from Jackson Laboratory (weight 584 
20-25g, age 8-10 weeks old) were used for the experiments and littermates controls 585 
were used in each experiment  (Reporting Summary). Except Drd2-cre:ribotag mice, all 586 
animals were housed in individual cages under controlled conditions of illumination (12 587 
h light/dark cycle), temperature and humidity. The animals were allowed free access to 588 
water and a standard laboratory diet (CD) (Scientific Animal Food & Engineering, 589 
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proteins 16%, carbohydrates 60% and fat 3%) or high fat diet (HFD) (Research Diets 590 
12492; 60% of calories from fat, 5.24 Kcal/g; Research Diets, New Brunswick, NJ) for 591 
12 weeks. Food intake and body weight were measured daily during the experimental 592 
phase in all experiments. 4 to 12 animals per group were used. The animals were 593 
euthanatized, and all the tissues were removed rapidly, frozen immediately on dry ice, 594 
and kept at -80ºC until analysis. All experiments and procedures involved in this study 595 
were reviewed and approved by the Ethics Committee of the University of Santiago de 596 
Compostela, in accordance with European Union normative for the use of experimental 597 
animals. 598 
 599 
Body composition and indirect calorimetry 600 
Body composition (white fat mass) was measured using a nuclear magnetic resonance 601 
system (Whole Body Composition Analyser; EchoMRI, Houston,TX). Measurements 602 
were performed before surgery and on the last day of the treatment. Energy expenditure, 603 
respiratory quotient (RQ) and locomotor activity were assessed using a calorimetry 604 
system (LabMaster; TSE Systems) 24,72.  605 
 606 
Temperature measurements, thermal imaging, cold exposure and thermoneutrality 607 
Interscapular temperature was assessed and was visualized using a high-resolution 608 
infrared camera (E60bx: Compact-Infrared-Thermal-Imaging-Camera; FLIR; West 609 
Malling, Kent, UK) and analyzed with a FLIR-Tools specific software package 73. Body 610 
temperature was recorded with a rectal probe connected to a digital thermometer (BAT-611 
12 Microprobe-Thermometer; Physitemp; NJ, USA). After the acute injection of 612 
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bromocriptine, rats were placed for 6 h in a special room with a stable temperature of 613 
4ºC 74.  D2r-cre mice were moved to a thermoneutral environment (30ºC with relative 614 
humidity of 45-52%) in order to eliminate the extra-metabolism needed to defend the 615 
body temperature at lower temperatures 75. 616 
 617 
Intracerebroventricular treatments 618 
Animals were anesthetized by an intraperitoneal injection of a mixture of ketamine-619 
xylazine (ketamine 100 mg/kg rat body weight + xylazine 15 mg/kg rat body weight; 620 
ketamine 8 mg/kg mouse body weight + xylazine 3 mg/kg mouse body weight). 621 
Intracerebroventricular (ICV) cannulae aimed at the lateral ventricle were 622 
stereotaxically implanted in rats using the following coordinates: 1.3 mm posterior to 623 
bregma, 1.9 mm lateral to the midsagittal suture, and a depth of 3.5 mm; and in mice: 624 
0.6 mm posterior to bregma, 1.2 mm lateral to the midsagittal suture, and a depth of 2 625 
mm 72,76. Animals received vehicle (DMSO 100 mM) or bromocriptine mesylate (20, 40 626 
or 80 µg/animal; Tocris, St Louis, MO, USA). In other experiments, the orexin receptor 627 
1 inhibitor (SB-334867; 4 µg/mouse, Tocris, St Louis, MO, USA), orexin (10 628 
µg/mouse, Bachem, Bubendorf, Switzerland) 32,77, the specific PKA activator Sp-629 
cAMPS (90 ng/rat dose; Tocris, St Louis, MO, USA) 35,36, prolactin (1 or 10 µg/mouse, 630 
San Diego, CA, USA) or cilostamide (10 µg/mouse, AlfaAesar, Massachusetts, USA) 39 631 
were also administered ICV. For chronic experiments, a catheter tube was connected 632 
from the brain infusion cannulae to an osmotic minipump flow moderator (model 2002 633 
for a 14-days period for rats and model 1007D for a 7-days period for mice; Alzet 634 
Osmotic Pumps, Durect, Cupertino, CA). These pumps had a flow rate of 0.5 µl/hour 635 
during the days of treatment. The minipump was inserted in a subcutaneous pocket on 636 
the dorsal surface of the animal that we created using blunt dissection and the incision 637 
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was closed with surgical sutures. After surgery, animals were kept warm until they fully 638 
recovered.  639 
 640 
Peripheral treatments 641 
For peripheral treatments, rats received an intraperitoneal administration of 642 
bromocriptine (40 µg/rat) and mice (5 mg/kg). Mice received an intraperitoneal 643 
administration of clozapine-N-oxide (CNO; 1 mg/kg, Sigma-Aldrich; St.Louis, MO) 644 
and clozapine (1mg/kg, Sigma-Aldrich; St. Louis, MO) 27. Pharmacological inactivation 645 
of β3-adrenoreceptor was performed by subcutaneous administration of the specific 646 
antagonist SR59230A (Tocris, St Louis, MO, USA) at a dose of 3 mg/kg 24. 647 
 648 
Stereotaxic microinjections in specific hypothalamic nuclei 649 
Rats were placed in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA) 650 
under ketamine-xylazine anesthetics. Bromocriptine (40 µg/rat) and the specific PKA 651 
inhibitor H-89 (62 ng/rat; Sigma Chemical, USA) were injected stereotaxically with a 652 
25-gauge needle (Hamilton, Reno, NV, USA) connected to a 1 µl syringe. We targeted 653 
the lateral hypothalamus area and zona incerta (LHA/ZI) and the ventromedial 654 
hypothalamus area (VMH) 72. The coordinates used to reach the LHA/ZI in rats were 655 
(anterior to the bregma (AP), -2.85 mm; lateral to the sagittal suture (L), ±2 mm; and 656 
ventral from the surface of the skull (DV), -8.1 mm) and to reach the VMH were (AP, -657 
2.85 mm; L, ±0.6 mm; DV, -10 mm). The coordinates used to reach the LHA/ZI in mice 658 
were (AP, -1.3 mm; L, ±1.1 mm; DV, -5.2 mm), to reach the MBH were (AP-1.5 mm; 659 
L, ±0.2 mm; DV, -6 mm) and to reach the DMH were (AP-1.9 mm; L, ±0.3 mm; DV, -5 660 
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mm). The incision was closed with sutures and acetylsalicylic acid (Bayer, Leverkusen, 661 
Germany) 150 mg/kg was injected intraperitoneally after surgery as a painkiller. 662 
 663 
Stereotaxic microinjection of adenoviral expression vectors 664 
Adenoviral vectors D2R knockdown (3.5 x 1010 PFU/ml) or the vector controls (3.5 x 665 
1010 PFU/ml) 78 and adenoviral vectors containing the constitutively active form of 666 
S6K1 (4.77 x 1010 PFU/ml) or null controls (1.8 × 1010 PFU/ml) 43 were used. To 667 
modify the expression of D2R specifically in vgat and vglut2 neurons, we injected Ad-668 
hSyn-DIO-D2R-EGFP (1.0 x 1010 PFU/ml), Ad-hSyn-DIO-shD2R-EGFP (1.0 x 1010 669 
PFU/ml) and Ad-hSyn-DIO-EGFP (1.0 x 1010 PFU/ml) (Vector Builder) under cell 670 
specific cre promoters. These viral vectors were injected in the hypothalamic nuclei as 671 
described in the previous section. 672 
 673 
FACS sorting and Quantitative RT-PCR analyses 674 
 Viral infection was confirmed using FACS. The tuberal region of the hypothalamus of 675 
Vgat-cre + Ad-EGFP LHA/ZI mice were microdissected and enzymativcally 676 
dissociated using Papain Dissociation System (Worthington, Lakewood, NJ) to obtain 677 
single cell suspensions 79. FACS was performed using an EPICS ALTRA Cell Sorter 678 
Cytometer device (BD Bioscience). The sort decision was based on measurements of 679 
EGFP fluorescence (excitation: 488 nm; 50 mW; detection: EGFP bandpass 530/30 nm, 680 
autofluorescence bandpass 695/40 nm) by comparing cell suspensions from non-681 
infected brain sites (i.e., cortex) and infected brain sites (i.e., the hypothalamus), as 682 
indicated in Figure 4g. For each animal 150 to 400 EGFP-positive cells were sorted 683 
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directly into 10 μl of extraction buffer: 0.1% Triton X100 (Sigma-Aldrich) and 0.4 unit/ 684 
μl RNaseOUTTM (Life technologies). RNAs obtained from FACS-sorted EGFP-685 
negative and positive cells were reversed transcribed using SuperScript® III Reverse 686 
Transcriptase (Life Technologies) and a linear preamplification step was performed 687 
using the TaqMan® PreAmp Master Mix Kit Protocol (P/N 4366128, Applied 688 
Biosystems). Real-time PCR was carried out on Applied Biosystems 7900HT Fast Real-689 
Time PCR system using exon-boundary-specific TaqMan® Gene Expression Assays 690 
(Applied Biosystem): VGat (Slc32a1-Mm00494138_m1), Dopamine receptor 2 (Drd2-691 
Mm00438545_m1) and VGlut2 (Slc17a6-Mm00499876_m1). Control housekeeping 692 
genes: R18S (r18S-Mm03928990_g1) and Actin (Actb-Mm00607939_s1). 693 
 694 
Designer Receptors Exclusively Activated by Designer Drugs  695 
The hM3Dq coding sequences were cloned into a mCherry vector upstream of the 696 
mCherry sequence to generate C-terminal mCherry fusion proteins (Addgene, 697 
Cambridge, USA). The hM3Dq-mCherry coding sequence was amplified by PCR, and 698 
the amplicons and a cre-inducible AAV vector with a human Synapsin 1 promoter was 699 
packaged in serotype 8: 7.53X1012 PFU/ml genome copies per ml and was prepared and 700 
tittered at the Universidad Autónoma de Barcelona (Barcelona, Spain). Ketamine-701 
xylazine anesthesized male D2-cre mice 80 were placed in a stereotaxic frame (David 702 
Kopf Instruments). The CRE-dependent AAVs were injected bilaterally into the 703 
LHA/ZI of all mice. The viral particles (1 μl, 7.53X1009 PFU/ml) were infused over 15 704 
minutes. Three weeks after the injection of the AAVs, mice received CNO (1 mg/kg of 705 
body weight) or vehicle- i.p. injection.  706 
 707 
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Adenoviral injection in the BAT of mice 708 
Adenoviral vectors for knocking down D2R (1.0 x 109 PFU/ml) or the vector controls 709 
(1.0 x 109 PFU/ml) were injected in a volume of 50 µl bilaterally into the BAT in mice 710 
under ketamine-xylazine anesthetics 21.  711 
 712 
PET imaging system  713 
Whole-body micro PET/CT images were acquired with the Albira PET/CT Preclinical 714 
Imaging System (Bruker Biosping; Woodbidge, CT, USA) and the experimental 715 
procedure with rats were performed in the same conditions. BAT area was delineated by 716 
using image tools implemented the AMIDE Software (http://amide.sourceforge.net/) to 717 
generate a three-dimensional spherical volume of interest with radius of 6mm and 718 
centered on the BAT area. Mean standardized uptake values (SUV) were computed. The 719 
PET-CT analysis was performed in the Molecular Imaging Unit of the Department of 720 
Nuclear Medicine of University of Santiago de Compostela. 721 
 722 
Dissection of brain areas 723 
The brains were removed and immediately frozen and stored at −80°C until further 724 
processing. Then, the brain was placed in a brain matrix with a ventral surface on top 725 
under a dissecting microscope. The LHA/ZI were removed from the whole 726 
hypothalamus by cutting between the rostral and caudal limits of the median eminence 727 
parallel to the base of the hypothalamus and 1 mm to each lateral side of the median 728 
eminence. The depth of each section isolated was around 1 mm thick in mice and 3mm 729 
thick in rats brain 81,25. 730 
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 731 
Western Blot analysis 732 
Tissues were homogenized using a TissueLyser II (Qiagen, Tokyo, Japan) in cold RIPA 733 
buffer (containing 200 mMTris/HCl (pH 7.4), 130 mM NaCl,10%(v/v) glycerol, 734 
0.1%(v/v) SDS, 1%(v/v) Triton X-100, 10 mM MgCl2) with anti-proteases and anti-735 
phosphatases (Sigma-Aldrich;St.Louis, MO). The tissue lysates were centrifuged for 30 736 
minutes at 18000 g in a microfuge at 4ºC. Brown adipose tissue (BAT), muscle, cortex, 737 
VMH and LHA total protein lysates were subjected to sodium–dodecyl sulfate-738 
polyacrylamide gels (SDS–PAGE), then electrotransferred on a PVDF membrane and 739 
probed successively with the following antibodies: UCP1, FGF21, PRDM16, D2R, 740 
Myostatin (Abcam, Cambridge, UK); PGC1α, JNK, MCH (Santa Cruz Biotechnology, 741 
CA, USA); pAKT (Ser473), AKT, phospho-S6 ribosomal protein, S6 ribosomal protein, 742 
phospho-SAPK/JNK(Thr183/Tyr185, phospho-CREB (Ser133) (Cell Signaling, USA); 743 
GAPDH (Merck Millipore, Darmstadt, Germany); mTOR, β-actin, α-tubulin (Sigma- 744 
Aldrich, St. Louis,MO); Myogenin (DSHB, Iowa, USA); Orexin A (Bioss Antibodies, 745 
Massachusetts, USA); PDE3B (Invitrogen, CA, USA) after incubating the membranes 746 
with 5% BSA blocking buffer. For protein detection we used horseradish-peroxidase-747 
conjugated secondary antibodies (Dako Denmark, Glostrup, Denmark). Specific 748 
antigen-antibody bindings were visualized using chemiluminescence method according 749 
to the manufacturer´s instructions (Pierce ECL Western Blotting Substrate, Thermo 750 
Scientific, USA). Values were expressed in relation to β-actin or GAPDH (for cortex, 751 
VMH and LHA) and α-tubulin (for muscle and BAT) protein levels. For details related 752 
to antibodies and dilutions please see Reporting Summary. Uncropped images of all 753 
immunoblots are provided in Supplementary fig. 11. 754 
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 755 
Blood determinations 756 
The quantitative determination of mouse/rat prolactin concentrations in plasma were 757 
determined by ELISA using reagents kits and methods provided by Mybiosurce 758 
(Catalog Number MBS 580033; P.R., China). 759 
 760 
Histomorphology 761 
BAT samples were fixed 24 hour in 10% formalin buffer and then were dehydrated and 762 
embedded in paraffin by a standard procedure. Sections of 3 µm were made in a 763 
microtome and staining in a standard Hematoxilin/Eosin Alcoholic (BioOptica) 764 
procedure following manufacturer instructions 24. Sections were observed and 765 
photographed using a Provis AX70 microscope (Olympus, Corp, Tokyo, Japan). BAT 766 
quantification was analyzed using Image-J software (National Institutes of Health, 767 
USA).  768 
 769 
Immunohistochemistry and immunofluorescence  770 
Detection of UCP1 in BAT was performed using anti-UCP1 (1:500; Abcam, 771 
Cambridge, UK) and the detection was done with an anti-rabbit antibody conjugated 772 
with Alexa 488 (1:200; Molecular Probes; Grand Island, NY, USA) 24. Images were 773 
observed and photographed using a Provis AX70 microscope (Olympus, Corp, Tokyo, 774 
Japan) and were quantified with Frida software (Framework for Image Dataset 775 
Analysis). 776 
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Animal brains were fixed by perfusion followed by inmersion-fixed in formol-calcium 777 
for 24 hours. After that were dehydrated and embedded in paraffin and using a thick 778 
section of 3 µm were cut and mounted (Vibratome Series 1000, The Vibratome 779 
Company, St Louis, MO, USA) 82. Sections were incubated overnight at 4ºC with anti-780 
phospho-S6 ribosomal (Cell Signaling, USA) diluted 1:200 in EnVision Flex Antibody 781 
diluent (DAKO). After washes, sections were incubated with LSAB-DAKO secondary 782 
for 30 min. Also brains were processed and immunohistochemistry assays were 783 
performed to visualize protein levels of c-FOS (Santa Cruz, CA, USA) at a dilution of 784 
1:500 72. Images were observed and photographed using a Provis AX70 microscope 785 
(Olympus, Corp, Tokyo, Japan). Cellular counting was performed in the brain using 786 
Image-J software (National Institutes of Health, USA).  787 
To test specific nuclei injection, we used immunofluorescence. To visualize green 788 
positive signals sections were incubated with rabbit antibody against green fluorescent 789 
protein (GFP) (1:200; Abcam, Cambridge, UK) and we used a goat anti-rabbit Alexa 790 
488 (1:200; Molecular Probes; Grand Island, NY, USA). 791 
Detection of mCherry was performed with an immunofluorescence procedure, using a 792 
rabbit anti-cherry (1:200; Abcam; Cambridge, UK). Detection was done with an anti-793 
rabbit antibody conjugated with Alexa 488 (1:200; Molecular Probes; Grand Island, 794 
NY, USA). 795 
Tissue preparation, immunofluorescence and quantification were performed as 796 
described  26. The following primary antibodies were used : mouse anti-HA (1:1000, 797 
Covance, #MMS-101R), chicken anti-GFP (1:500, Life technologies (#A10262), rabbit 798 
anti-VGlut2 (1:500, Synaptic Systems, #135402), anti-VGat (1:1000, Synaptic Systems, 799 
#131013), anti-orexin-A (1:500, Millipore, Darmstadt, Germany #AB3098) and anti-800 
MCH (1:500, Sigma, #M8440). LHA and ZI sections were identified using a mouse 801 
34 
 
brain atlas and sections comprised between -1.34 to -1.70 mm from bregma were 802 
analyzed.  803 
 804 
In situ hybridation  805 
Coronal hypothalamic sections (16 μm) were cut on a cryostat and immediately stored 806 
at −80 C until hybridization. For MCH, and prepro-OX mRNA detection we employed 807 
the specific antisense oligodeoxynucleotides (Table 1). These probes were 3′-end 808 
labeled with [α-35S]deoxy-ATP using terminal deoxynucleotidyl transferase. The 809 
frozen sections were fixed with 4% paraformaldehyde in 0.1 m phosphate buffer (pH 810 
7.4) at room temperature for 30 min. They were then dehydrated using 70%, 80%, 90%, 811 
95%, and absolute ethanol (5 min each). The hybridization was carried out overnight at 812 
37 C in a moist chamber. Hybridization solution contained 5 × 105 (prepro-OX) or 1 × 813 
106 cpm (MCH) per slide of the labeled probe, 4× standard saline citrate (SSC), 50% 814 
deionized formamide, 1× Denhardt’s solution, 10% dextran sulfate, and 10 μg/ml 815 
sheared, single-stranded salmon sperm DNA. Afterward, the hybridization sections 816 
were sequentially washed in 1× SSC at room temperature, four times in 1× SSC at 42 ºC 817 
(30 min/wash), and once in 1× SSC at room temperature (1 h), and then rinsed in water 818 
and ethanol. Finally, the sections were air-dried and exposed to Hyperfilm β-Max 819 
(Amersham International, Little Chalfont, UK) at room temperature for 4–6 d 83. Images 820 
were quantified using Image-J software (National Institutes of Health, USA). 821 
 822 
Patient selection 823 
First, we conducted a retrospective chart review of patients affected by 824 
hyperprolactinemia seen at the Endocrinology Department of the University Clinic of 825 
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Navarra between January 2007 and December 2013. All patients were of Caucasian 826 
origin. Pregnant and lactating women were excluded. Patients with hyperprolactinemia 827 
secondary to drugs (including neuroleptics, antidepressants, opiates and gastrointestinal 828 
prokinetics) or mixed-secreting tumours or those already receiving dopamine agonists at 829 
the first visit to our hospital as well as those not completing a 12-month follow-up 830 
period were excluded from the analysis. Furthermore, patients with multiple pituitary 831 
hormone deficiencies and/or the presence of other concomitant causes of overt 832 
hypogonadism were excluded to avoid the potential effect of hormonal replacement 833 
therapy on body weight control and metabolic changes. In this respect, patients with 834 
previously known treatment with hypoglycemic agents to control glucose metabolism 835 
abnormalities or anti-obesity drugs for body weight loss were also excluded. After all 836 
the exclusions, 31 patients with newly diagnosed prolactinoma comprised the study 837 
sample of the retrospective analysis (26 females and 5 males with an age range between 838 
21-61 years). All patients underwent a detailed anamnesis, physical exploration and 839 
metabolic evaluation (Reporting Summary). The diagnosis was based on signs and 840 
symptoms of hyperprolactinemia, high serum prolactin concentrations and magnetic 841 
resonance imaging (MRI) demonstrating a pituitary tumor84. After the diagnosis patients 842 
received cabergoline, a potent long-acting dopamine agonist that is more effective and 843 
better tolerated than bromocriptine85. Cabergoline was administered orally at a starting 844 
dose of 0.25 mg once weekly at bedtime for the first week, twice weekly during the 845 
second week and escalating until administration of 0.5 mg twice weekly at bedtime. 846 
Prolactin normalization was achieved with this treatment protocol in all patients.  847 
 848 
In order to examine in more detail, the potential impact of dopamine agonism on body 849 
weight, body composition, resting energy expenditure and metabolic changes a 850 
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prospective study was carried out in patients affected by hyperprolactinemia seen at the 851 
same Endocrinology Department of the University Clinic of Navarra between January 852 
2014 and May 2017  (Reporting Summary). The same inclusion and exclusion criteria 853 
and treatment protocol as for the retrospective study were applied. In this case, however, 854 
body composition as well as resting energy expenditure determinations were performed 855 
at baseline when the diagnosis was established as well as at the follow-up visits at 3, 6 856 
and 12 months after treatment instauration with cabergoline. In the prospective study, 857 
22 patients of Caucasian origin with newly diagnosed prolactinoma were enrolled (19 858 
females and 3 males with an age range between 25-63 years). All patients were non-859 
smokers and did not show signs of infection. Both clinical studies were approved, from 860 
an ethical and scientific standpoint, by the Hospital's Ethical Committee and were 861 
conducted in accordance with the principles of the Declaration of Helsinki with patients 862 
giving their informed consent for participation. 863 
 864 
Anthropometry 865 
Body weight was measured with a digital scale to the nearest 0.1 kg, while height was 866 
measured to the nearest 0.1 cm with a Holtain stadiometer (Holtain Ltd., Crymych, UK) 867 
to calculate the BMI. Waist circumference was determined at the midpoint between the 868 
iliac crest and the rib cage on the midaxillary line. Body fat was estimated by air-869 
displacement-plethysmography (Bod-Pod®, Life Measurements, Concord, California, 870 
USA) 86.  871 
 872 
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Indirect calorimetry 873 
In the prospective study the resting energy expenditure (REE) and respiratory quotient 874 
(RQ) were determined by indirect calorimetry after a 12-h overnight fast using an open-875 
air-circuit ventilated canopy measurement system (Vmax29, SensorMedics Corporation, 876 
Yorba Linda, California) at baseline and at follow-up visits after treatment start 877 
adjusting also for body composition87.  878 
 879 
Blood determinations 880 
Plasma samples were obtained by venipuncture after an overnight fast. Glucose was 881 
analyzed based on enzymatic spectrophotometric reactions by an automated analyzer 882 
(Hitachi Modular P800, Roche, Basel, Switzerland). Insulin was measured by means of 883 
an enzyme-amplified chemiluminescence assay (IMMULITE®, Diagnostic Products 884 
Corp., Los Angeles, CA). The intra-and interassay coefficients of variation (CV) were 885 
4.2% and 5.7%, respectively. Insulin resistance was calculated using the homeostasis 886 
model assessment (HOMA-IR) index. Circulating prolactin concentrations were 887 
determined by a microparticle chemiluminescent assay (Prolactin II, Elecsys, Cobas E, 888 
Roche Diagnostics GmbH., Mannheim, Germany) with a normal range of 1-27 µg/L for 889 
women and of 1-20 µg/L for men together with intra- and interassay CV of 2.3 and 890 
5.9%, respectively. Triglycerides, total cholesterol, high-density lipoprotein (HDL)-891 
cholesterol and low-density lipoprotein (LDL)-cholesterol levels were calculated as 892 
previously described 88. 893 
 894 
Statistics 895 
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Results are given as mean ± standard deviation (SD). Samples or animals were excluded 896 
whether their values were outside the ± 2-fold standard deviation 89, or whether an 897 
objective experimental failure was observed; studies were not blinded to investigators or 898 
formally randomized. The number of animals used in each study is listed in the figure 899 
legends. To test if the populations follows a Gaussian distribution, a normality test was 900 
performed (Kolgomorov-Smirnov test for n between 5-7; Shapiro-Wilk test for n ≥7) 90. 901 
For normal distributions, parametric test was used; for two population comparisons, an 902 
unpaired t tests (two-tailed for treatment and phenotyping experiment, one-tailed 903 
otherwise) were used as indicated in figure legends 91-93; for multiple comparison test, a 904 
one-way ANOVA followed by Bonferroni post hoc multiple comparison test, was 905 
performed 94. For non-Gaussian distributions  was used; Man-Whitney test were used 906 
for two comparison test 95, and Kruskal-Wallis followed by Dunn post hoc test for 907 
multiple comparison 96,97. Data analysis was performed using GraphPad Prism Software 908 
Version 5.0 (GraphPad, San Diego, CA). The correlation between locomotor activity 909 
and energy expenditure was analyzed by Pearson’s correlation (normally distributed 910 
data) or Spearman’s rank correlation (non-normally distributed data) coefficients (r). 911 
Data analysis was performed using the SPSS version 20.0 sofware statistical package 912 
(SPSS, Chicago, IL) (Reporting Summary). 913 
 In patients, comparison of changes at baseline and after treatment administration at 914 
different time points was carried out by two-tailed paired Student’s t-tests between pre- 915 
and post-treatment values and Wilcoxon signed rank test as appropriate. The 916 
calculations were performed using the SPSS/Windows version 15.0 statistical package 917 
(SPSS, Chicago, IL) (Reporting Summary). A p value < 0.05 was considered 918 
statistically significant. 919 
 920 
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Data availability 921 
The data that support the findings of this study are available from the corresponding 922 
author upon request. Correspondence and requests for materials should be addressed to 923 
Ruben Nogueiras.  924 
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Figure legends 951 
Figure 1. Chronic central infusion of bromocriptine reduces diet-induced obesity. 952 
(a-d) Effect of a 14-day intracerebroventricular infusion of bromocriptine (BC) (40 953 
µg/rat/day) and subcutaneous injection of SR59230A hydrochloride (3 mg/kg) on body 954 
weight (a), cumulative food intake (b) (n=8); representative histology of BAT lipid 955 
content and quantification of lipid droplet average area (c) (n=7), scale bars, 200 µm; 956 
protein levels of BAT UCP1, FGF21, PRDM16 and PGC1α in rats fed a chow diet (d) 957 
(n=7). (e-l) Effect of a 10-day intracerebroventricular infusion of bromocriptine (40 958 
µg/rat/day) and subcutaneous injection of SR59230A hydrochloride (3 mg/kg) on 959 
cumulative food intake (e); body weight change (f); white mass gain (g); energy 960 
expenditure (EE) (h); respiratory quotient (RQ) (i), locomotor activity (j) (n=7 Veh, n=8 961 
BC and n=7 BC+ SR59230A hydrochloride treatment); representative histology of BAT 962 
lipid content and quantification of lipid droplet average area (k) (n=7 each treatment), 963 
scale bars, 200 µm; protein levels of BAT UCP1, FGF21, PRDM16 and PGC1α (l) (n=7 964 
Veh, n=8 BC and n=7 BC+ SR59230A hydrochloride treatment) in rats fed a high fat 965 
diet (HFD). (m-q) Effect of a 7-day intracerebroventricular infusion of bromocriptine 966 
(40 µg/mouse/day) on body weight change (m); cumulative food intake (n); white mass 967 
change (o); representative histology of BAT lipid content and quantification of lipid 968 
droplet average area (p) scale bars, 200 µm, and protein levels of BAT UCP1 (q) (n= 5 969 
WT Veh and WT BC mice, n= 4 TKO Veh and n=6 TKO BC mice). Protein data were 970 
expressed in relation (%) to control (vehicle-treated) animals. α-tubulin was used to 971 
normalize protein levels. Dividing lines indicate splicings within the same gel. Values 972 
are represented as the mean ± SD. Statistical differences according to a one-way 973 
ANOVA followed by Bonferroni post hoc multiple comparison test (a,b,c,e,f,g,h,i,k,j), 974 
analysis of covariance (ANCOVA) with non-fat mass as covariate (h), or a Kruskal-975 
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Wallis followed by Dunn post hoc test for multiple comparison (d,e,l,m,n,o,p,q). Values 976 
are represented as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (a,f). 977 
 978 
Figure 2. Stimulation of D2R in the LHA/ZI stimulates BAT activity. (a-e) Effect of 979 
the specific injection of bromocriptine (BC) (40 µg/rat) in the LHA/ZI on body weight 980 
change (a) and food intake (b) (n=9 each treatment); infrared thermal images and 981 
quantification of BAT interscapular temperature (c) (n=5); representative histology of 982 
BAT lipid content and quantification of lipid droplet average area (d) (n=5), scale bars, 983 
200 µm; protein levels of BAT UCP1 (e) (n=7) after 24 hours. (f-h) Effect of the 984 
specific injection of bromocriptine (40 µg/rat) in the VMH on body weight change (f), 985 
food intake (g), and infrared thermal images and quantification of BAT interscapular 986 
temperature after 24 hours (h) (n=9 each treatment). (i-t) Representative mCherry 987 
expression in the hypothalamic LHA/ZI after stereotaxic injection of hSYN-DIO-988 
hM3D(Gq)-mCherry AVV, scale bar 0.2 mm (i). Effect of the stereotaxical injection of 989 
hSYN-DIO-Hm3D(Gq)-mCherry AVV in the LHA/ZI of D2R-CRE mice on body 990 
weight change (j), food intake and water intake (k), infrared thermal images and 991 
quantification of BAT interscapular temperature (l), body temperature (m) (n=7 per 992 
group); respiratory quotient (n), locomotor activity (o) and energy expenditure (p) (n=5) 993 
and correlation between energy expenditure and locomotor activity in the dark phase, in 994 
the light phase and energy expenditure during 2 hours of light phase (Pearson 995 
correlation test) (q); representative histology of BAT lipid content (r) (n=6) scale bars, 996 
200 µm; protein levels of BAT UCP1 (s), plasma prolactin levels (t) (n= 7 Veh and n=6 997 
CNO) after 24 hours and body temperature and BAT interscapular temperature in cold 998 
exposure (4ºC) (n=9) (u). Protein data were expressed in relation (%) to control 999 
(vehicle-treated) animals. α- tubulin was used to normalize protein levels. Dividing lines 1000 
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indicate splicings within the same gel. The experiments were repeated five times (i). 1001 
Data are mean ± SD. Statistical differences according to a two-sided Student´s t-test 1002 
(e,f,g,h,j,l,m,u) or two-sided Mann-Whitney U test (a,b,c,d,k,n,o,p,q,r,s). 1003 
 1004 
Figure 3. Knock down of D2R in the LHA/ZI blunts bromocriptine-induced weight 1005 
loss. (a) Representative photomicrograph of brain section showing the injection of the 1006 
viral vectors that encodes GFP expression precisely placed in the LHA/ZI, scale bar, 0.1 1007 
mm and (b) D2R protein levels in the LHA/ZI 3 weeks after the viral infection (n=7 per 1008 
group). (c-i) Effect of the injection of adenoviral particles encoding for GFP- or D2R-1009 
KD in the LHA/ZI of rats treated with ICV bromocriptine (BC) (40 µg/rat) on body 1010 
weight change (c), food intake (d), WAT weight (e)  and infrared thermal images and 1011 
quantification of BAT interscapular temperature (f) (n= 6 GFP Veh, n=8 GFP BC, n=9 1012 
D2R-KD Veh and n=9 D2R-KD BC); representative histology of BAT lipid content and 1013 
quantification of lipid droplet average area (g) (n=5) scale bars, 200 µm; BAT UCP1 1014 
protein levels (h) (n= 6 in each treatment) and c-FOS immunoreactive cells (IR) in the 1015 
raphe pallidus (RPa) and inferior olive (IO) with representative sections (i) (Gi, 1016 
gigantocellular reticular nucleus; IO, inferior olive; py, pyramidal tract; RPa, raphe 1017 
pallidus; scale bar, 100 µm (n=5). (j) Double immunostaining of HA and orexin, MCH, 1018 
Vgat and Vglut2 in D2R-Cre: Ribotag mice, scale bars: 100 µm, insets, 40 µm, high 1019 
magnification, 8 µm). α-tubulin and β-actin were used to normalize protein levels. 1020 
Protein data were expressed in relation (%) to control (vehicle-treated) animals. 1021 
Dividing lines indicate splicings within the same gel. The experiments were repeated six 1022 
times (a,j). Data are mean ± SD. Statistical differences on the basis of a one-way 1023 
ANOVA followed by Bonferroni post hoc multiple comparison test (c,d,f,g) or two-1024 
tailed Student´s t-test (b,e,h,i). 1025 
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Figure 4. D2R action in GABAergic neurons requires orexin to modulate BAT. (a) 1026 
Photomicrograph showing the colocalization of GFP and Vglut2 in the LHA/ZI. (b-e) 1027 
Effect of the injection of Ad-hSyn-DIO-EGFP or Ad-hSyn-DIO-D2R-EGFP in the 1028 
LHA/ZI of vglut2-ires-cre mice on body weight change (b), food intake (c), BAT 1029 
temperature (d) (n=10) and BAT UCP1 protein levels (e) (n=4). (f) Photomicrograph 1030 
showing the colocalization of GFP and Vgat in the LHA/ZI. (g) Profiles from sorted 1031 
non-infected/EGFP (cortex) and infected/EGFP sites (hypothalamus) and mRNA 1032 
expression of Vgat, Vglut2 and Drd2 in Vgat-ires and Vglut2-ires cre mice injected 1033 
with Ad-hSyn-DIO-EGFP in the LHA/ZI (n=4). (h-k) Effect of the injection of Ad-1034 
hSyn-DIO-EGFP or Ad-hSyn-DIO-D2R-EGFP in the LHA/ZI of vgat-ires-cre mice on 1035 
body weight change (h), food intake (i), BAT temperature (j) (n=12) and BAT UCP1 1036 
protein levels (k) (n=4). (l-o) Effect of the injection of Ad-hSyn-DIO- EGFP or Ad-1037 
hSyn-DIO-shD2R-EGFP in the LHA/ZI of vgat-ires-cre mice on body weight change 1038 
(l), food intake (m) (n=7), BAT temperature (n) and BAT UCP1 protein levels (o) (n= 1039 
6). (p-t) Effect of a 24-hour ICV injection of bromocriptine (BC) (40 µg) on body 1040 
weight change (p), food intake (q), infrared thermal images and quantification of BAT 1041 
temperature (r), histology of BAT lipid content and quantification of lipid droplet 1042 
average area (s) (n=4); and BAT UCP1 protein levels (t) in wild type (n=4) and orexin 1043 
knockout (n=6) mice. (u-x) Effect of the injection of AAV-hSYN-DIO-Hm3D(Gq)-1044 
mCherry and the ICV injection of the orexin receptor antagonist SB-334867 (4 µg) on 1045 
body weight change (u) and infrared thermal images and quantification of BAT  1046 
temperature (v) (n=5-6); histology of BAT lipid content and quantification of lipid 1047 
droplet average area (w) and immunostaining of UCP1 and quantification in BAT (x) 1048 
(n=8) after 24 hours. Dividing lines indicate splicings within the same gel. The 1049 
experiments were repeated six times (a,h). Data are mean ± SD. Statistical differences 1050 
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on the basis of a two-tailed Student´s t-test (b,c,d,h,i,j,k), a Kruskal-Wallis followed by 1051 
Dunn post hoc test for multiple comparison (c,p,q), two-way ANOVA (r), two-sided 1052 
Mann-Whitney U test (e,g,l,m,n,o,s,t) or a one-way ANOVA followed by Bonferroni 1053 
post hoc multiple comparison test (u,v,w,x).  1054 
 1055 
Figure 5. Protein kinase A mediates the effects of bromocriptine on BAT. (a-d) 1056 
Phosphorylated levels of CREB in the LHA/ZI after: 2-hour ICV (a) and 24-hour 1057 
specific injection of bromocriptine (BC) (40 µg) in the LHA/ZI (n=7) (b); injection of 1058 
AAV-hSYN-DIO-hM3D (Gq)-mCherry and the ICV injection of SB-334867 (4 µg) 1059 
(n=5-6) (c); ICV injection of orexin (OX) (10 µg) and SB-334867 (4 µg) after 24 hours 1060 
(n=5-9) (d). (e-j) Effect of the ICV injection of BC (40 µg) and Sp-cAMPS (90 ng) on 1061 
body weight change (e), food intake (f) and white mass gain (g) (n= 9); and BAT 1062 
temperature (h) (n=7-8); histology of BAT lipid content and quantification of lipid 1063 
droplet area (i) and immunostaining of UCP1 and quantification in BAT (j) (n=7) after 1064 
24 hours. (k-p) Effect of the LHA/ZI injection of the specific PKA inhibitor H-89 (62 1065 
ng) on body weight change (k), food intake (l), white mass gain (m), and BAT 1066 
temperature (n) (n=11-12); histology of BAT lipid content and quantification of lipid 1067 
droplet area (o) (n= 10), and protein levels of BAT UCP1 (p) (n=7) after 24 hours. (q) 1068 
Effect of the injection of AAV-hSyn-DIO-hM3D (Gq)-mCherry in the LHA/ZI of D2R-1069 
cre mice on PDE3B levels in the LHA/ZI (n=6). (r-s) Effect of the ICV injection of 1070 
Cilostamide (10 µg) on body weight (r) and food intake (s) (n=7). (t-v) Effect of the 1071 
injection of AAV-hSyn-DIO-Hm3D (Gq)-mCherry in the LHA/ZI of D2R-cre mice and 1072 
the ICV injection of Cilostamide (10 µg) on body weight (t), food intake (u) and BAT 1073 
temperature (v) (n=6). (w-z) Effect of the injection of Ad-hSyn-DIO-EGFP or Ad-1074 
hSyn-DIO-D2R-EGFP in the LHA/ZI of Vgat-ires-cre mice and ICV Cilostamide (10 1075 
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µg) on body weight (w), food intake (x), BAT  temperature (y) and energy expenditure 1076 
(EE) after 24hours (z) (n= 7-8). Dividing lines indicate splicings within the same gel. 1077 
Data are mean ± SD. Statistical differences according to a two-tailed Student´s t-test 1078 
(a,b,q,r,s), a one-way ANOVA followed by Bonferroni post hoc multiple comparison 1079 
test (c,e,f,g,h,i,j,w,x,y), a Kruskal-Wallis followed by Dunn post hoc test for multiple 1080 
comparison (d, t,u,v,) or two-sided Mann-Whitney U test (k,l,m,n,o,p) and analysis of 1081 
covariance (ANCOVA) with body weight as covariate (z). 1082 
 1083 
Figure 6. S6 mediates the effects of bromocriptine on BAT. (a-i) rpS6 1084 
phosphorylated levels in the LHA/ZI after: ICV injection of bromocriptine (BC) (40 µg) 1085 
assessed by immunohistochemistry (n=7) (a) and western blot (n=4) (b); 24-hour 1086 
specific injection of BC (40 µg) in the LHA/ZI (n=7) (c); injection of Ad-GFP or Ad-1087 
shD2R in the LHA/ZI of rats treated with ICV bromocriptine (40 µg) (n= 6 GFP Veh, 1088 
n=7 GFP BC, n=7 D2R-KD Veh and n=7 D2R-KD BC) (d); 24-hour ICV injection of 1089 
BC (40 µg) in wild type (n=4) and orexin (OX) knockout mice (n=6) (e); injection of 1090 
AAV-hSYN-DIO-hM3D (Gq)-mCherry and the ICV injection of SB-334867 (4 µg) 1091 
(n=4 Veh, n=4 CNO and n=5 CNO+SB-334867) (f); ICV injection of OX (10 µg) and 1092 
SB-334867 (4 µg) (n=6) (g); LHA/ZI injection of the specific PKA inhibitor H-89 (62 1093 
ng) (n=7) (h); and ICV injection of BC (40 µg) and the specific PKA activator Sp-1094 
cAMPS (90 ng) after 24 hours (n=6) (i). (j) Total and rpS6 phosphorylated levels in the 1095 
LHA/ZI 3 weeks after the viral infection (n=7). (k-o) Effect of the injection of 1096 
adenoviral particles encoding for Null or S6K1 in the LHA/ZI of rats treated with ICV 1097 
BC (40 µg) on body weight change (k), food intake (l) and infrared thermal images and 1098 
quantification of BAT interscapular temperature (m) (n= 8 ad null Veh, n=9 ad null BC, 1099 
n=8 ad S6K1 Veh and n=9 ad S6K1 BC), histology of BAT lipid content and 1100 
47 
 
quantification of lipid droplet average area (n), and BAT UCP1 protein levels (o) (n=7). 1101 
Dividing lines indicate splicings within the same gel. Data are mean ± SD. Statistical 1102 
differences according to a two-tailed Student´s t-test (a,c,d), a two-sided Man-Whitney 1103 
test (b,e,h,j), a Kruskal-Wallis followed by Dunn post hoc test for multiple comparison 1104 
(f,g,i) or a one-way ANOVA followed by Bonferroni post hoc multiple comparison test 1105 
(k,l,m,n,o). 1106 
 1107 
Figure 7. Cabergoline decreases body weight and increases resting energy 1108 
expenditure in patients. (a) Waterfall plot of the body weight changes experimented 1109 
by each patient (1-31) of the retrospective study between baseline and following 0.5 mg 1110 
twice weekly cabergoline treatment for 12 months. (b) Waterfall plot of the body weight 1111 
changes experimented by each patient (1-21) of the prospective study during the first 3 1112 
months of cabergoline treatment instauration with 0.5 mg cabergoline twice weekly. (c) 1113 
REE in patients before and after cabergoline treatment compared to the REE predicted 1114 
from the Harris Benedict equation. (d) Correlation between REE and weight loss in 1115 
patients treated with cabergoline.  1116 
 1117 
 1118 
1119 
48 
 
Table 1. Clinical, anthropometric and metabolic characteristics of hyperprolactinemic 1120 
patients before and after one year of treatment initiation with cabergoline. 1121 
Condition/Variable Patient at diagnosis Cabergoline treatment Stat signif. 
(n = 31) Baseline      After 12 months P value 
Gender (m/f) 5/26 5/26 0.732
Age (years) 35 ± 10 36 ± 11 0.846 
Body weight (kg) 67.5 ± 17.1 64.3 ± 14.2 0.045 
BMI (kg/m2) 24.9 ± 5.4 23.8 ± 4.6 0.043 
Prolactin (μg/L) 99.5 ± 16.7 8.3 ± 9 <0.001 
Glucose (mmol/L) 5.8  ±  1.7 4.6  ±  1.5 0.038 
Insulin (pmol/L) 92 ± 48 79 ± 54 0.040 
HOMA-IR 3.32 ± 2.15 2.26 ± 1.38 0.039 
Triglycerides (mmol/L) 2.0 ± 0.9 1.3 ± 0.5 0.008 
Total cholesterol (mmol/L) 5.0 ± 1.1 4.2 ± 0.6 0.041 
LDL cholesterol (mmol/L) 3.2 ± 1.0 2.1 ± 0.7 0.033 
HDL cholesterol (mmol/L) 1.1 ± 0.4 1.4 ± 0.5 0.075 
    
    
Condition/Variable Patient at  Cabergoline treatment Stat. signif.  P value 
(n = 21) Baseline 3 months 12 months  (a)       (b) 
Gender (m/f) 3/18 3/18 3/18 0.806 
Age (years) 40 + 12 40 + 12 41 + 11 0.799 
Body weight (kg) 70.5 ± 10.6 64.6 ± 12.3 64.1 ± 15.0 0.044    0.045 
BMI (kg/m2) 25.8 ± 5.1 24.2 ± 4.2 23.6 ± 5.3 0.042    0.043 
WC (cm) 90 ± 11 84 ± 9 83 ± 10 0.047    0.046 
Body fat (%) 34.7 ± 5.6 29.5 ± 4.2 28.9 ± 6.1 0.040    0.039 
REE (kJ/d) 5997 ± 704 6703 ± 800 6532 ± 779 0.046    0.045 
REE (kJ/kg/d) 85.1 ± 9.2 104.2 ± 9.8 102.7 ± 8.6 0.041    0.040 
REE (kJ/kg FFM/d) 90.0 ± 7.7 105.4 ± 5.6 101.9 ± 6.3 0.037    0.038 
RQ (vCO2/vO2) 0.83 ± 0.06 0.84 ± 0.05 0.83 ± 0.08 0.621    0.665 
Prolactin (μg/L) 111.5 ± 12.7 9.3 ± 3.1 8.3 ± 5.0 <0.001  <0.001 
Glucose (mmol/L) 5.7  ±  0.8 4.1  ±  0.3 4.5  ±  0.5 0.042    0.04 
Insulin (pmol/L) 93 ± 56 71 ± 44 75 ± 52 0.037    0.036 
HOMA-IR 3.53 ± 1.98 2.15 ± 1.59 2.43 ± 1.80 0.038    0.039 
Triglycerides (mmol/L) 2.1 ± 1.0 1.1 ± 0.3 1.3 ± 0.4 0.022    0.026 
Total cholesterol (mmol/L) 5.0 ± 0.9 4.7 ± 0.8 4.9 ± 1.0 0.278    0.301 
LDL cholesterol (mmol/L) 3.0 ± 1.1 2.5 ± 0.6 2.6 ± 0.8 0.293    0.352 
HDL cholesterol (mmol/L) 1.0 ± 0.6 1.2 ± 0.7 1.1 ± 0.5 0.348    0.386 
     
     
BMI, body mass index; WC, waist circumference; REE, resting energy expenditure; RQ, respiratory quotient; 1122 
vCO2/vO2, dimensionless ratio between carbon dioxide production and oxygen consumption; HOMA-IR, 1123 
homeostatic model assessment. Data are mean ± SD; comparison of baseline with (a) 3 months following 1124 
cabergoline treatment initiation and (b) 12 months after cabergoline treatment start; according to a two-sided 1125 
Student’s t-tests between pre- and post-treatment values and Wilcoxon signed rank test. 1126 
 1127 
  1128 
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